Latest news with #Biologics
Yahoo
6 days ago
- Business
- Yahoo
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas, July 24, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules." Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic "self/non‑self" checks largely unaddressed. LENSai's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome "humanness" scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Study Highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity "self" scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Read the full case study: [link] About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," "potential," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@
National Post
6 days ago
- Business
- National Post
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk--Long Before the Clinic
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENS ai ™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. Article content 'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENS ai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.' Article content Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed. Article content LENS ai 's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Article content Study Highlights Article content 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Article content Read the full case study: Article content [ Article content link Article content ] Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Article content Forward-Looking Statements Article content This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Article content Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Article content Article content Article content Article content Contacts Article content Investor Relations Contact Article content Article content Article content Article content
Time of India
23-07-2025
- Business
- Time of India
Syngene Q1 profit up 59% to Rs 87 crore
Representative image BENGALURU: Syngene International, a subsidairy of Biocon , reported a 59 per cent year-on-year increase in profit after tax to Rs 87 crore in the first quarter ended June 2025, aided by revenue growth and a tax benefit from the transfer of gratuity funds to an employee trust. Revenue from operations rose 11 per cent to Rs 875 crore during the period. Ebitda grew 19 per cent year-on-year to Rs 224 crore, with margins improving to 25 per cent from 23 per cent a year earlier. CEO Peter Bains said the growth was led by the conversion of pilot programs into long-term contracts in the Research Services division. The company also progressed operations at its Biologics Unit III facility in Bengaluru and prepared for the launch of its Bayview site in the US later this year. It commissioned a new peptide laboratory during the quarter. The company said it underwent over 20 client and regulatory audits in Q1, including a USFDA GCP inspection of its Human Pharmacology Unit with no observations. Its Biologics facility received an Establishment Inspection Report with a Voluntary Action Indicated outcome. CFO Deepak Jain said operating Ebitda margins held around 24 per cent, supported by revenue growth and cost optimisation. Syngene said it remains on track to meet its full-year guidance. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
&w=3840&q=100)
Business Standard
23-07-2025
- Business
- Business Standard
Syngene Q1 PAT up 59% to ₹87 crore, operational revenue rises 11%
Biocon arm Syngene International's consolidated net profit rose to Rs 87 crore, up 59 per cent year-on-year (Y-o-Y) in the first quarter of the financial year 2026 (Q1 FY26) ended June 30, according to a company statement. Revenue from operations grew 11 per cent Y-o-Y to Rs 875 crore. The performance was driven by continued conversion of pilot programmes into long-term contracts within the Research Services business. The Q1 FY25 profit after tax (PAT) excludes an exceptional item of Rs 21 crore (net of tax) relating to a final settlement from an insurance claim. The reported revenue stood at Rs 892 crore in Q1 FY26, up 10 per cent. The company's EBITDA (earnings before interest, taxes, depreciation, and amortisation) stood at Rs 224 crore—a 19 per cent increase—driven by revenue growth and cost optimisation. The EBITDA margin stood at 25 per cent. Bains added that Syngene continues to strengthen and expand its scientific platform capabilities, including the launch of a state-of-the-art, dedicated peptide laboratory, while remaining mindful of ongoing macroeconomic factors. Syngene has appointed Chethan Yogesh as the secretary and compliance officer of the company with effect from July 23. Yogesh was previously associated with technology firms including Wipro and IBM. The company also completed a USFDA GCP inspection of its Human Pharmacology Unit with no observations and received a favourable Voluntary Action Indicated (VAI) outcome for its Biologics facility. Syngene noted that over 20 client and regulatory audits in Q1 FY26 reinforced its global quality standards. Deepak Jain, chief financial officer, Syngene International Limited, said: 'The current quarter's PAT includes a tax benefit arising from transfer of gratuity funds to the Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.' Syngene announced its results after market close on Wednesday. During the session, the company's shares were up 0.50 per cent at Rs 679.65 apiece on the BSE.
Business Upturn
23-07-2025
- Business
- Business Upturn
Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY
Syngene International Limited reported strong financial results for the quarter ended June 30, 2025 (Q1 FY26), led by higher revenue and improved margins. For the quarter, the company's revenue from operations rose 11% year-on-year (YoY) to ₹875 crore, compared to ₹790 crore in Q1 FY25. Reported revenue, including other income, stood at ₹892 crore, up 10% YoY. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) came in at ₹224 crore, growing 19% from ₹188 crore last year. The EBITDA margin improved to 25% from 23% YoY, driven by revenue growth and cost optimization. Net profit (PAT) surged 59% to ₹87 crore from ₹54 crore in the same quarter last year. The PAT margin expanded to 10% from 7% YoY. Key Financials: YoY comparison Metric Q1 FY25 Q1 FY26 YoY Change (%) Revenue from operations (₹ Cr) 790 875 ↑ 11% Reported revenue (₹ Cr) 808 892 ↑ 10% EBITDA (₹ Cr) 188 224 ↑ 19% EBITDA margin (%) 23 25 ↑ 200 bps Net profit (PAT) (₹ Cr) 54 87 ↑ 59% PAT margin (%) 7 10 ↑ 300 bps Commenting on the results, Peter Bains, Managing Director and CEO, highlighted that the performance was in line with expectations, supported by continued conversion of pilot programs into longer-term contracts in the Research Services business and progress in the Biologics manufacturing division. Deepak Jain, CFO, noted that the quarter's profitability also benefitted from a tax credit, and the company maintained a strong balance sheet to invest in capabilities and technology. Other business highlights included the successful completion of USFDA inspections, inauguration of a state-of-the-art peptide laboratory, and recognition by TIME and Statista as one of the world's most sustainable companies. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
